Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E23.83 EPS (ttm)6.70 Insider Own0.10% Shs Outstand758.86M Perf Week0.76%
Market Cap121.14B Forward P/E15.21 EPS next Y10.50 Insider Trans-2.82% Shs Float757.96M Perf Month2.62%
Income5.16B PEG2.15 EPS next Q2.11 Inst Own82.50% Short Float1.29% Perf Quarter-2.58%
Sales20.06B P/S6.04 EPS this Y0.90% Inst Trans-0.72% Short Ratio2.76 Perf Half Y16.15%
Book/sh33.83 P/B4.72 EPS next Y13.01% ROA7.50% Target Price176.26 Perf Year31.23%
Cash/sh35.61 P/C4.48 EPS next 5Y11.10% ROE21.00% 52W Range106.12 - 172.23 Perf YTD0.74%
Dividend3.16 P/FCF21.25 EPS past 5Y8.20% ROI10.20% 52W High-7.32% Beta0.58
Dividend %1.98% Quick Ratio4.60 Sales past 5Y6.50% Gross Margin80.00% 52W Low50.42% ATR3.10
Employees17900 Current Ratio5.00 Sales Q/Q6.40% Oper. Margin34.70% RSI (14)59.52 Volatility1.74% 2.12%
OptionableYes Debt/Eq1.19 EPS Q/Q25.60% Profit Margin25.70% Rel Volume0.98 Prev Close157.72
ShortableYes LT Debt/Eq1.17 EarningsJan 27 AMC Payout35.90% Avg Volume3.55M Price159.63
Recom2.40 SMA203.51% SMA501.90% SMA20014.00% Volume3,480,190 Change1.21%
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Apr-24-13Reiterated Deutsche Bank Buy $108 → $115
Apr-15-13Reiterated Barclays Equal Weight $90 → $105
Apr-08-13Reiterated RBC Capital Mkts Outperform $95 → $105
Jan-25-13Upgrade Argus Hold → Buy $96
Jan-24-13Reiterated UBS Buy $96 → $98
Sep-12-12Downgrade Robert W. Baird Outperform → Neutral $84
Sep-10-12Upgrade UBS Neutral → Buy $80 → $96
Mar-02-15 05:10PM  Investors short Juno Therapeutics, Amgen stocks, but that may not be bad news at bizjournals.com
04:30PM  Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data PR Newswire
04:15PM  Former Dendreon CEO, Amgen scientists team up on new immunotherapy startup at bizjournals.com
04:01PM  Amgen Announces Launch Of New Neulasta® (Pegfilgrastim) Delivery Kit PR Newswire
03:02PM  Amgen's Kyprolis Fares Better than Velcade in Study - Analyst Blog Zacks
02:05PM  Apple bull pulls brake CNBC
01:19PM  Amgen: Blood cancer drug Kyprolis beats rival's in study AP
01:17PM  Midday Glance: Biotechnology companies AP
01:17PM  Cancer drug shows promise CNBC
07:02AM  Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen PR Newswire
12:31AM  Amgen Sees Positive Results From Kyprolis Study at The Wall Street Journal
Mar-01-15 11:15PM  Amgen Biosimilar Rheumatoid Arthritis Therapy Shows Positive Results at The Wall Street Journal
10:25PM  Amgen Multiple Myeloma Drug Kyprolis Tops Rival in Study at TheStreet
09:13PM  Amgen Sees Positive Results From Kyprolis Study at The Wall Street Journal
08:22PM  Amgen's Kyprolis Outperforms Rival Drug In Study at Forbes
08:12PM  Amgen says a study found its cancer drug more effective than rival drug at Los Angeles Times
07:01PM  Amgen says Kyprolis doubles progression-free survival vs Velcade Reuters
07:00PM  Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma PR Newswire
Feb-28-15 07:36PM  Amgen's Kyprolis Under EU Review - Analyst Blog Zacks
12:35PM  Stock Market Video Analysis for Week Ending 2/27/15 Yahoo Finance Contributors
Feb-27-15 06:02PM  Final Glance: Biotechnology companies AP
05:30PM  Bellevue city manager: Keeping Expedia in Bellevue a 'top priority' at bizjournals.com
03:45PM  Expedia may move to Amgen's former Seattle campus at bizjournals.com
11:10AM  Early Glance: Biotechnology companies AP
09:30AM  The Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron - Press Releases Zacks
09:00AM  Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer PR Newswire
Feb-26-15 04:05PM  Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma PR Newswire
01:25PM  Short Sellers Come Back To Biotech Stocks Benzinga
01:04PM  AMGEN INC Financials EDGAR Online Financials
11:20AM  Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog Zacks
11:07AM  Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog Zacks
09:45AM  Rigel Pharma CEO pulls back the curtain on drug deal with Bristol-Myers at American City Business Journals
09:25AM  Short Sellers Increase Bets Against Biotech as Shares Continue to Rise at 24/7 Wall St.
Feb-25-15 06:04PM  Amgen Drug Shows Positive Results in Late-Phase Study at The Wall Street Journal
04:44PM  Amgen Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis PR Newswire
04:04PM  Amgen To Present At The Cowen And Company 35th Annual Health Care Conference PR Newswire
Feb-23-15 07:58PM  Gilead Sciences, Inc., Amgen, Inc., Biogen Idec Inc Among Billionaires 5 Hottest Biotech Picks at Insider Monkey
07:44PM  [video]Jim Cramer's 'Mad Money' Recap: Calm Down, There's No Nasdaq Bubble at TheStreet
11:06AM  Big pharma invests big money in research and development Market Realist
10:05AM  Third Point ups its stake in Amgen Market Realist
Feb-21-15 07:08PM  10-K for Amgen, Inc. Company Spotlight
03:04PM  Ariad Pharmaceuticals, Inc., Quest Diagnostics Inc, Amgen, Inc.: Sarissa Capitals Top Stock Picks and New Moves at Insider Monkey
Feb-19-15 05:06PM  AMGEN INC Files SEC form 10-K, Annual Report EDGAR Online
10:40AM  Actavis (ACT) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
Feb-18-15 06:04PM  A Look At Dan Loeb's Diversified 13F Benzinga
Feb-17-15 05:55PM  CVS urges cost controls for new cholesterol drugs Reuters
04:59PM  CVS girds for battle over cholesterol drugs at MarketWatch
09:29AM  Daniel Loeb's Third Point Boosted Stakes of Amgen, Alibaba in 4Q at Barrons.com
Feb-16-15 08:36AM  If Pfizer's Right, Hospira Biosimilar Gold Rush Begins at Forbes
Feb-12-15 04:10PM  Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog Zacks
08:44AM  Brookdale scales up in response to industry dynamics Market Realist
Feb-11-15 04:22PM  Amgen Announces FDA Advisory Committees To Review Talimogene Laherparepvec For The Treatment Of Patients With Metastatic Melanoma PR Newswire
10:40AM  Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog Zacks
Feb-10-15 04:38PM  Regeneron Earnings Growth Falls Short, But Eylea Sales, '15 Outlook Are Solid Investor's Business Daily
11:01AM  Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea at Investor's Business Daily
04:22AM  Career Booster for CFOs: a Stint Abroad at The Wall Street Journal
Feb-06-15 12:31PM  Fat Pharma: Pfizer-Hospira and the top 10 overpriced drug deals ever at Fortune
10:10AM  Stock Market News for February 06, 2015 - Market News Zacks
07:18AM  How Obamacare Made Hospira A Lucrative Target For Pfizer at Forbes
Feb-05-15 06:20PM  bluebird bio's Thalassemia Drug Gets Breakthrough Status - Analyst Blog Zacks
05:33PM  Generic-Drug Makers Soar, And It's Easy To See Why at Investor's Business Daily
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Biogen, Celgene, AbbVie and Gilead - Press Releases Zacks
Feb-04-15 04:25PM  Amgen Reveals Positive Results on Biosimilar Candidate - Analyst Blog Zacks
03:55PM  In speed mode, FDA approves Pfizers big new drug early at Fortune
12:36PM  Safe biotech plays CNBC
11:47AM  Biotech Stock Roundup: Biogen Impresses with 4Q Results, Gilead & AbbVie HCV Drugs in Focus - Analyst Blog Zacks
11:21AM  Merck (MRK) Beats on Q4 Earnings but Guidance Falls Short - Analyst Blog Zacks
10:45AM  Gilead Dividend and Buyback Different From Amgens Strategy at 24/7 Wall St.
10:22AM  Will Dividend Investors Find Gilead? at Barrons.com
Feb-03-15 06:14PM  [$$] Amgen Biosimilar Rheumatoid Arthritis Therapy Shows Positive Results at The Wall Street Journal
04:57PM  Amgen: Its biosimilar version of Humira about as effective AP
04:49PM  Paying Dividends: Gilead Initiates First Quarterly Payout at Barrons.com
04:01PM  Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis PR Newswire
Jan-29-15 04:40PM  Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH Initiative To Improve Diagnosis And Care For People With Familial Hypercholesterolemia PR Newswire
Jan-28-15 04:46PM  Wednesday's Market Recap Yahoo Finance Contributors
03:37PM  Correction: Earns-Amgen story AP
12:53PM  Wait, I Thought Amgen Reported Solid Earnings? at Barrons.com
12:30PM  Amgen (AMGN) Stock Declines Today Despite Earnings Beat at TheStreet
10:00AM  Amgen Beats on Q4 Earnings & Revenues, Maintains Outlook - Analyst Blog Zacks
07:49AM  Amgen (AMGN) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
Jan-27-15 07:10PM  Amgen Profit Rises 27% on Higher Sales of Key Drugs at The Wall Street Journal
06:40PM  Amgen tops Street 4Q forecasts AP
05:45PM  Amgen fourth-quarter earnings, revenue beat estimates at Los Angeles Times
05:20PM  Amgen Beats Q4 Expectations Benzinga
05:12PM  Amgen profit tops expectations on Enbrel sales, tax credit Reuters
05:12PM  Stocks Weaken Late; Apple Jumps After Hours at Investor's Business Daily
05:01PM  Updates, advisories and surprises at MarketWatch
05:00PM  Amgen Inc Earnings Call scheduled for 5:00 pm ET today CCBN
05:00PM  After-hours buzz: AT&T, Apple, Yahoo & more at CNBC
04:45PM  Amgen (AMGN) Stock Rises in After-Hours Trading Today on Fourth-Quarter Earnings Beat at TheStreet
04:28PM  Amgen profit beats forecasts at MarketWatch
04:17PM  Amgen Climbs On Q4 Beat at Barrons.com
04:16PM  AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:02PM  Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma PR Newswire
04:01PM  Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70 PR Newswire
12:31PM  What to Expect When Amgen (AMGN) Reports Fourth-Quarter Earnings After Market Close Today at TheStreet
10:19AM  Pfizer Beats on Q4 Earnings, Guides Below Expectations - Analyst Blog Zacks
07:07AM  Q4 2014 Amgen Inc Earnings Release - After Market Close CCBN
Jan-26-15 12:00PM  TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog Zacks
08:02AM  Can CAR-T Therapy Live Up To The Biotech IPO Hype? at Investor's Business Daily
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BALTIMORE DAVIDDirectorFeb 19Option Exercise42.135,000210,65036,159Feb 23 04:13 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Option Exercise42.1384,0003,538,920258,641Feb 12 09:09 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Sale152.6922,0003,359,116218,102Feb 12 09:09 PM
COFFMAN VANCE DDirectorFeb 06Option Exercise42.135,000210,65038,460Feb 06 06:23 PM
HERRINGER FRANK CDirectorFeb 05Option Exercise42.135,000210,65025,449Feb 05 08:11 PM
HERRINGER FRANK CDirectorFeb 05Buy152.293,000456,8702,000Feb 05 08:11 PM
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Option Exercise56.644,130233,91122,719May 22 05:15 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Sale112.834,130465,98418,589May 22 05:15 PM
Bradway Robert AChairman, CEO and PresidentMay 12Buy111.7789499,919185,013May 12 08:33 PM
Michael A KellyActing CFOApr 28Sale110.452,065228,07241,041Apr 29 05:48 PM
de Carbonnel FrancoisDirectorMar 06Option Exercise54.4410,000544,35025,364Mar 07 05:23 PM
de Carbonnel FrancoisDirectorMar 06Sale126.691,000126,69018,343Mar 07 05:23 PM